Webinar: A Song of Fire and Splice: The CRISPR Saga
hosted by the Washington,  DC Chapter

Tuesday, March 27, 2026

12:00 pm - 1:00 pm Eastern

11:00 am - 12:00 pm Central

10:00 am - 11:00 am Mountain

9:00 am - 10:00 am Pacific

Program:
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene-editing technology adapted from a bacterial immune system that allows scientists to make precise changes to DNA, like cutting, adding, or removing genetic material, offering immense potential for treating genetic diseases (e.g., sickle cell), developing diagnostics, and engineering organisms.  Ownership of this crucial technology means billions of dollars in revenue.  So, of course, there has been and continues to be a war over patent priority, that has been waged for over a decade by four separate groups of purported inventors, and at present there is no end in sight.

In particular, Broad Institute, Harvard University, and the Massachusetts Institute of Technology (collectively, "Broad") and The University of California/Berkeley, the University of Vienna, and Emmanuelle Charpentier (collectively, "CVC"), are currently back before the PTAB after the Federal Circuit vacated an earlier decision in Broad’s favor in a second interference between them.

The two other parties, ToolGen (a Korean company) and Sigma-Adrich each have separate pending interferences against Broad and CVC, with a possible further interferences between ToolGen and Sigma.

In addition to this history the talk will consider the arguments and relative strengths and weaknesses of the parties’ positions and the consequences should any of the parties ultimately be awarded priority.

Speaker:

Kevin Noonan, Ph.D., Partner, McDonnell, Boehnen, Hulbert & Berghoff LLP Kevin E. Noonan, Ph.D. is a partner at McDonnell Boehnen Hulbert & Berghoff LLP in Chicago and co-Chair of its Biotechnology and Pharma Practice Group.  Dr. Noonan is experienced in all aspects of patenting and in biotechnology and chemistry, representing pharmaceutical and biotechnology companies, as well as universities. He is a founder of the biotechnology and pharma patent law and news weblog, Patent Docs (www.patentdocs.org).  In addition to his blog, Dr. Noonan writes and lectures extensively on biotechnology patent law. Kevin earned a BS from the State University of New York, a Ph.D. in molecular biology from Princeton University, and a JD, cum laude, from the John Marshall Law School in Chicago.

LES Members Price: FREE

(LES International Members please contact info@les.org for a code)

Non-Members: $69

Want to view this and all LES webinars (recorded and LIVE) for free  - Join LES Today!

Email Consent:  By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.